This guidance has been updated and replaced by NICE technology appraisal guidance on cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1165).
This guidance has been updated and replaced by NICE technology appraisal guidance on cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1165).